Stem Cell Technologies And Applications Will Generate $15.8bn In 2019, A New Visiongain Analysis Predicts

13 September 2018
Pharma

A new visiongain report forecasts that the worldwide stem cell technological and applications market will generate revenues of $15.8bn in 2019. That forecast and others appear in Stem Cell Technologies and Applications Market Report 2016-2026: Hype vs Reality for That Transformative Technology with Vast R&D Pipeline and Expanding Use of HSCT and Cord Blood Banking, published in November 2015. Visiongain is a business information publisher and consultancy in London, UK.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Stem cells have been seen for many years as an upcoming and potentially transformative technology. In 2015, the market has yet to realise its great potential, but stem cell technologies remain on the cusp of significant market expansion. Factors such as the increasing use of hematopoietic stem cell transplantation (HSCT), the launch of current pipeline therapies and the expanding use of cord blood banking services and stem cell-based assays will stimulate this market over the next ten years.

“However the industry has many barriers to overcome. Current reimbursement and regulatory systems will need to be updated to adapt to the unique challenges posed by these non-traditional therapies. In addition, companies will have to attract the attention of Big Pharma, which sometimes remains wary of this exciting but potentially risky field.”

Visiongain’s updated analysis gives revenue forecasting to 2026 for the overall stem cell technologies and applications market. It also shows revenue predictions from 2015 to 2026 for the following five submarkets:

• Cancer treatment (oncology)
• Cardiovascular therapy
• CNS uses
• Other therapies
• Non-therapeutic applications.

The report also provides revenue forecasts to 2026 for six stem cell therapies:

• MSC-100-IV (Mesoblast)
• Hearticellgram-AMI (Pharmicell)
• CardioRel (Reliance Life Sciences)
• Osteocel Plus (NuVasive)
• Trinity Evolution and Elite (Orthofix)
• CARTISTEM (MEDIPOST).

That investigation shows interviews with the Human Stem Cells Institute (HSCI), Apceth, MEDIPOST, Harvard Stem Cells Institute and the Stem Cell Program at Boston’s Children’s Hospital. It also discusses research and development, reviewing the most promising advances. The study also discusses leading companies, assessing their activities and potentials.

Stem Cell Technologies and Applications Market Report 2016-2026 adds to visiongain’s analysis on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.

Recent News

“Global Cell Therapy Technologies market set to grow to $23bn by 2024” says new Visiongain report

Cell therapy technologies are used across various research areas including gene therapy, cancer vaccines, regenerative medicine, biologics and others. Increasing global disease burdens and the need for more personalised & precision medicine has led to massive growth in the cell technology market, which is likely to increase over the next decade.

19 February 2020

Read

“Global Asthma & COPD market set to grow to $49 bn by 2025” says new Visiongain report

The Asthma and COPD market has the potential to bring several blockbuster drugs to the marketplace due to the increasingly segmented sub-groups of patients.

17 February 2020

Read

“Global Rheumatoid Arthritis Drugs market estimated to grow at a CAGR of 0.6% in the second half of the forecast period” says Visiongain report

Another factor driving the growth in the market is the discovery of new molecules that are involved in the disease process, and hence, new strategies for treating the disease.

17 February 2020

Read

Visiongain assesses that the Contract Research Organisations (CROs) market will generate revenues of $38.0 billion in 2020

Global clinical research organizations market was valued at $34.9 billion in 2019 and is projected to grow at a CAGR of 9.5% during the forecast period 2020-2030.

12 February 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever